BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced new data from its prospective, multicenter DECIDE1 study in which DecisionDx®-Melanoma test results influenced 85% of clinicians’ decisions regarding the sentinel lymph node biopsy (SLNB) surgical procedure, demonstrating the role of the test’s results in guiding risk-aligned patient management decisions.

Akeso, Inc. (9926. HK) (“Akeso”) announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR-mutated who failed to prior EGFR-TKI treatment.

Revance Therapeutics, Inc. today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for DAXXIFY™ for the treatment of cervical dystonia.

Bausch Health Companies Inc. today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev.

Ochre Bio , an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.

On a recently updated FDA list of artificial intelligence (AI) enabled medical devices, GE Healthcare had the highest number of authorizations, with 42 listed 510(k) clearances to date, in the United States.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer.

Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.

Asymchem and AUM Biosciences jointly announced today the completion of their first GMP production campaign of AUM601.

Meeting adjourned to November 17, 2022 , at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022 , who have not yet voted, to vote by 11:59 p.m., Eastern Time on November 16, 2022.